<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772951</url>
  </required_header>
  <id_info>
    <org_study_id>HKQ201813</org_study_id>
    <nct_id>NCT03772951</nct_id>
  </id_info>
  <brief_title>The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia</brief_title>
  <official_title>The Efficacy for Execution Function and Genetic Mechanism of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study group received antipsychotic drugs combined with Computerized Cognitive Remediation&#xD;
      Therapy (CCRT) for 4 times/week for 45 minutes each time. The control group only received&#xD;
      antipsychotic drugs. For a total of 12 weeks. Brain Derived Neurotrophic Factor (BDNF) and&#xD;
      Tropomyosin-related kinase B (Trk B) genes in peripheral blood were detected in both groups&#xD;
      before and after treatment. Clinical symptoms and executive function assessment were&#xD;
      performed in both groups before and after treatment. The relevance of genes and their effects&#xD;
      on downstream protein expression levels led to a molecular genetic mechanism for the efficacy&#xD;
      of Computerized Cognitive Remediation Therapy (CCRT) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the cognitive disorders of chronic schizophrenia, the most reported is the executive&#xD;
      dysfunction of the prefrontal lobe. There is increasing evidence that Computerized Cognitive&#xD;
      Remediation Therapy (CCRT) has a significant improvement in the implementation of&#xD;
      schizophrenia, but the specific mechanism is unknown. Therefore, this study plans to select&#xD;
      154 patients with chronic schizophrenia who were hospitalized for a long time. They were&#xD;
      randomly divided into two groups. The study group received antipsychotic drugs combined with&#xD;
      Computerized Cognitive Remediation Therapy (CCRT) for 4 times/week for 45 minutes each time.&#xD;
      The control group only received antipsychotic drugs. For a total of 12 weeks. brain-derived&#xD;
      neurotrophic factor (BDNF) and tyrosine receptor kinase B(TRK-B) genes in peripheral blood&#xD;
      were detected in both groups before and after treatment. Clinical symptoms and executive&#xD;
      function assessment were performed in both groups before and after treatment. The relevance&#xD;
      of genes and their effects on downstream protein expression levels led to a molecular genetic&#xD;
      mechanism for the efficacy of Computerized Cognitive Remediation Therapy (CCRT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The score of Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>the baseline</time_frame>
    <description>The score of Positive and Negative Syndrome Scale (PANSS) ranges from 19-133 and will be administered to assess the effectiveness of treatment. Do higher values represent a worse outcome. The subscales are summed to compute a total score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The score of Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>the end of 12 week</time_frame>
    <description>The score of Positive and Negative Syndrome Scale (PANSS) ranges from 19-133 and will be administered to assess the effectiveness of treatment. Do higher values represent a worse outcome.The subscales are summed to compute a total score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of Brain Derived Neurotrophic Factor (BDNF) used to assess the effectiveness of treatment</measure>
    <time_frame>the baseline</time_frame>
    <description>The Concentration of Brain Derived Neurotrophic Factor (BDNF) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The concentration of Brain Derived Neurotrophic Factor (BDNF) used to assess the effectiveness of treatment</measure>
    <time_frame>the end of 12 week</time_frame>
    <description>The Concentration of Brain Derived Neurotrophic Factor (BDNF) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The concentration of tyrosine receptor kinase B(TRK-B) used to assess the effectiveness of treatment</measure>
    <time_frame>the baseline</time_frame>
    <description>The Concentration of tyrosine receptor kinase B(TRK-B) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of tyrosine receptor kinase B(TRK-B) used to assess the effectiveness of treatment</measure>
    <time_frame>the end of 12 week</time_frame>
    <description>The Concentration of tyrosine receptor kinase B(TRK-B) will be administered to assess the effectiveness of treatment. Do higher values represent a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cognitive Remediation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Remediation Therapy</intervention_name>
    <description>Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.</description>
    <arm_group_label>Cognitive Remediation Therapy</arm_group_label>
    <other_name>CCRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>the course of disease is more than 2 years, the condition is stable for more than one month</description>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_label>Cognitive Remediation Therapy</arm_group_label>
    <other_name>CLZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-45 years old, Han nationality, male or female;&#xD;
&#xD;
          2. Comply with the American Diagnostic Criteria for Mental Disorder (DSM-V) diagnostic&#xD;
             criteria for &quot;schizophrenia&quot;;&#xD;
&#xD;
          3. The course of the disease and continued treatment with antipsychotic drugs for &gt; 2&#xD;
             years, stable for at least one month;&#xD;
&#xD;
          4. Positive NegativeSyndrome Scale (PANSS) &lt; 70 points;&#xD;
&#xD;
          5. intelligence quotient (IQ)&gt;80;&#xD;
&#xD;
          6. Cultural, social and educational backgrounds are sufficient to understand informed&#xD;
             consent and research content.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant diagnosis in addition to Diagnostic and Statistical Manual of Mental&#xD;
             Disorders-V other than schizophrenia;&#xD;
&#xD;
          2. Central nervous system organic diseases;&#xD;
&#xD;
          3. There are alcohol or other substances dependent or abused in the past two months,&#xD;
             causing significant social and cognitive impairment;&#xD;
&#xD;
          4. In the past year, there have been major life events such as widowhood;&#xD;
&#xD;
          5. Those who have serious suicide attempts (the third item of the (Hamilton Depression&#xD;
             Scale-17,HAMD-17) scale &quot;suicide&quot; â‰¥ 3 points);&#xD;
&#xD;
          6. The current patient's severe unstable physical disease;&#xD;
&#xD;
          7. pregnant women and lactating women;&#xD;
&#xD;
          8. Those who have received modified electroconvulsive therapy (MECT) and repetitive&#xD;
             Transcranial Magnetic Stimulation (rTMS) treatment in the past month;&#xD;
&#xD;
          9. Those who have been ineffective for more than 3 months of systemic psychotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tao shen, professor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Huangpu District Health and Wellness Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>guoqin hu, doctor</last_name>
    <phone>18817821826</phone>
    <email>huguoqin1990@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhenghui yi, professor</last_name>
    <phone>18017311007</phone>
    <email>yizhenghui1971@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huangpu District Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Ni, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03772951/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

